FLINT, Mich., May 18, 2016 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO) announced the publication of its collaborative study with the Perelman School of Medicine at the University of Pennsylvania on insurance coverage for hepatitis C.
Diplomat worked in collaboration with Penn Medicine researchers, revealing coverage differences in positively diagnosed hepatitis patients. The manuscript, titled "Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance," was published and chosen as the top editor's pick for the month of July 2016 in Clinical Gastroenterology and Hepatology.
The announcement was made during Paul Urick's presentation to the Association for Community Affiliated Plans (ACAP) on May 10, 2016. Urick is the Senior Vice President of Industry Relations, Pharmaceutical Account Management and Payor Strategies at Diplomat. During Urick's presentation, he also offered a valuable perspective on Diplomat's clinical programs and reporting, as well as showcased its current hepatitis C campaign.
The data was revealed through a prospective analysis of prescriptions submitted to Burman's Specialty Pharmacy, a Diplomat company, for patients in Pennsylvania, New Jersey, Delaware and Maryland. To determine the number and cause of denials, the team analyzed prescriptions from 2,321 patients between Nov. 1, 2014, and April 20, 2015, submitted by Burman's branches throughout the four states. Among those patients, 503 were covered by Medicaid, 795 by Medicare and 1,023 by commercial insurers.
Among the most common reasons for denial by Medicaid were "insufficient information to assess medical needs" (35.5 percent) and "lack of medical necessity" (35 percent). Although 90 percent or more of requests for hepatitis C drugs were approved for Medicare and commercial patients, it was found that a higher proportion of patients covered with Medicaid received an absolute denial. These findings are key to learning ways to develop a more efficient and informed health care delivery model.
Co-authors of the manuscript include senior author Vincent Lo Re III, Charitha Gowda, Paul N. Urick, Joshua T. Halladay, Amanda Binkley, Dena M. Carbonari, Kathryn Battista, Cassandra Peleckis, Jody Gilmore, Jason A. Roy, Jalpa A. Doshi, Peter P. Reese, K. Rajender Reddy and Jay R. Kostman.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management's good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat's filings with the Securities and Exchange Commission, including "Risk Factors" in Diplomat's Annual Report on Form 10-K for the year ended December 31, 2015, and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: "Take good care of patients, and the rest falls into place." Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit www.diplomat.is. Follow us on Twitter and LinkedIn and like us on Facebook.
Kali Lucas, Public Relations Coordinator
810.768.9580 | firstname.lastname@example.org
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/diplomats-hepatitis-c-coverage-study-with-penn-medicine-published-and-chosen-as-top-editors-pick-300271068.html
SOURCE Diplomat Pharmacy, Inc.